Parkman Healthcare Partners’s Standard BioTools LAB Stock Holding History

Parkman Healthcare Partners’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,670,401	Closed	-$4.53M	–	103
2024 Q1	$4.53M	Buy	1,670,401 +1,066,781	+177%	+$2.58M	0.56%	60
2023 Q4	$1.33M	Buy	603,620 +103,620	+21%	+$221K	0.19%	76
2023 Q3	$1.45M	Buy	+500,000	New	+$1.31M	0.27%	87
2020 Q2	–	Sell	-225,391	Closed	-$572K	–	83
2020 Q1	$572K	Sell	225,391 -174,609	-44%	-$574K	0.27%	63
2019 Q4	$1.39M	Buy	+400,000	New	+$1.41M	0.4%	58

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

Parkman Healthcare Partners's LAB Position: Q2 2024 in Review

Parkman Healthcare Partners sold out of Standard BioTools (LAB) in Q2 2024, closing a stake of 1,670,401 shares — an estimated $4.53M sold.

Parkman Healthcare Partners first reported a position in LAB in Q4 2019 and held it in 5 quarters. The position peaked at $4.53M in Q1 2024. 144 funds tracked by Wall St. Rank hold LAB as of Q2 2024.

Parkman Healthcare Partners reported no remaining Standard BioTools position as of Q2 2024 after selling out during the quarter.
Parkman Healthcare Partners sold 1,670,401 Standard BioTools shares in Q2 2024, an estimated $4.53M.
Parkman Healthcare Partners first reported a position in Standard BioTools in Q4 2019 and held it in 5 quarters.
Parkman Healthcare Partners's Standard BioTools position peaked at $4.53M in Q1 2024.
144 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2024.

Based on Parkman Healthcare Partners's 13F filing for Q2 2024, filed 14 Aug 2024.